| 摘要 |
The invention is directed to compounds of Formula (I): (see formula I) and pharmaceutically acceptable salts thereof, wherein R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C(O)C1-C6 alkyl, C(O)C2-C6 alkenyl or C(O)C2-C6 alkynyl; R2 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; R22 is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; R3 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, OC1-C6 alkyl, OC2-C6 alkenyl, or OC2-C6 alkynyl; R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, OC1-C6 alkyl, OC2-C6 alkenyl, OC2-C6 alkynyl or NR5R6; R5 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl; and R6 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, which act as CRF1 antagonists and are useful in the treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases.
|
